Drugs Made In America Acquisition Corp. 8-K

What Happened

• Drugs Made In America Acquisition Corp. filed an 8-K (April 28, 2026) reporting updated compensation terms for its Chief Financial Officer and Chief Executive Officer. The company updated a Statement of Work with Titan Advisory Services LLC for CFO services provided by Saleem Elmasri (originally appointed Nov. 17, 2025) and entered a CEO compensation agreement with Aleutian Equity Holdings LLC for CEO Roger E. Bendelac (appointed Feb. 28, 2026) on April 22, 2026.
• The updates confirm monthly cash pay that can accrue as obligations and specify equity awards that will be issued at the closing of the company’s initial business combination.

Key Details

• CFO (Saleem Elmasri / Titan Advisory Services LLC): original SoW provided $3,500 per month; Updated SoW (4/22/2026) leaves cash compensation unchanged and states accrued amounts are binding obligations. Because Titan was not issued the originally contemplated 100,000 shares, Elmasri (Titan’s designated recipient) is now entitled to 175,000 ordinary shares, earned upon execution of a definitive agreement and to be issued at closing of the company’s initial business combination (within 10 days thereafter).
• CEO (Roger E. Bendelac / Aleutian Equity Holdings LLC): CEO Compensation Agreement (4/22/2026) provides $4,500 per month — $2,500 payable currently and up to $2,000 may be deferred based on cash flow (deferred amounts accrue as binding obligations). Bendelac is entitled to 250,000 ordinary shares, earned upon execution of a definitive agreement and to be issued at closing of the company’s initial business combination (within 10 days thereafter).
• Agreements include customary provisions (indemnification, limitation of liability, dispute resolution, governing law).

Why It Matters

• Investors should note the company has contractual cash obligations that have accrued for executive pay and may continue to accrue (some amounts may be deferred but remain binding).
• The filing documents future equity issuances totaling 425,000 ordinary shares (175,000 to the CFO’s designee and 250,000 to the CEO’s designee) that are conditioned on execution of a definitive agreement and will be issued at the company’s initial business combination, potentially affecting share count and ownership when issued.
• These actions clarify executive compensation and alignment ahead of the company’s planned business combination, providing transparency on cash and equity commitments.